Yasunari Kashihara
Director/Miembro de la Junta en ONCOLYS BIOPHARMA INC. .
Fortuna: 507 895 $ al 30/04/2024
Perfil
Yasunari Kashihara is currently the Director & Head-Business Development at Oncolys BioPharma, Inc., Director at Unleash Immuno Oncolytics, Inc., Director at Precision Virologics, Inc., Director at Oncolys USA, Inc., and President at Liquid Biotech USA, Inc. He previously held positions as President & Chief Executive Officer at UMN Pharma, Inc., Licensing Manager at Santen Pharmaceutical Co., Ltd., and Pharmacological Researcher at Ciba-Geigy Japan Ltd.
He obtained an MBA from Trinity College Dublin in 2002 and completed undergraduate and graduate studies at Kyoto University.
He also graduated from Kyoto Pharmaceutical University in 1991 and Osaka Prefectural Semboku High School in 1984.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ONCOLYS BIOPHARMA, INC.
0.56% | 31/12/2023 | 115 000 ( 0.56% ) | 507 895 $ | 30/04/2024 |
Cargos activos de Yasunari Kashihara
| Empresas | Cargo | Inicio |
|---|---|---|
| ONCOLYS BIOPHARMA INC. | Director/Miembro de la Junta | 01/03/2008 |
Precision Virologics, Inc.
 Precision Virologics, Inc. BiotechnologyHealth Technology Precision Virologics, Inc. develops biologically targeted vaccines for emerging infectious diseases. The company was founded by David T. Curiel in 2017 and is headquartered in Saint Louis, MO. | Director/Miembro de la Junta | 01/04/2017 |
Liquid Biotech USA, Inc.
 Liquid Biotech USA, Inc. Medical/Nursing ServicesHealth Services Liquid Biotech USA, Inc. provides cancer diagnosing services. The private company is based in Philadelphia, PA. | Presidente | 01/11/2017 |
Unleash Immuno Oncolytics, Inc.
 Unleash Immuno Oncolytics, Inc. BiotechnologyHealth Technology Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO. | Director/Miembro de la Junta | 01/02/2018 |
| Oncolys USA, Inc. | Director/Miembro de la Junta | 01/01/2020 |
Antiguos cargos conocidos de Yasunari Kashihara.
| Empresas | Cargo | Fin |
|---|---|---|
| SANTEN PHARMACEUTICAL CO., LTD. | Corporate Officer/Principal | - |
| Ciba-Geigy Japan Ltd. | Corporate Officer/Principal | - |
| UMN PHARMA INC. | Presidente | - |
Formación de Yasunari Kashihara.
| Trinity College Dublin | Masters Business Admin |
| Kyoto University | Graduate Degree |
| Kyoto Pharmaceutical University | Graduate Degree |
| Osaka Prefectural Semboku High School | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SANTEN PHARMACEUTICAL CO., LTD. | Health Technology |
| ONCOLYS BIOPHARMA INC. | Health Technology |
| Empresas privadas | 6 |
|---|---|
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
| Ciba-Geigy Japan Ltd. | |
Unleash Immuno Oncolytics, Inc.
Unleash Immuno Oncolytics, Inc. BiotechnologyHealth Technology Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO. | Health Technology |
Precision Virologics, Inc.
Precision Virologics, Inc. BiotechnologyHealth Technology Precision Virologics, Inc. develops biologically targeted vaccines for emerging infectious diseases. The company was founded by David T. Curiel in 2017 and is headquartered in Saint Louis, MO. | Health Technology |
Liquid Biotech USA, Inc.
Liquid Biotech USA, Inc. Medical/Nursing ServicesHealth Services Liquid Biotech USA, Inc. provides cancer diagnosing services. The private company is based in Philadelphia, PA. | Health Services |
| Oncolys USA, Inc. |
- Bolsa de valores
- Insiders
- Yasunari Kashihara